The Food and Drug Administration (FDA) has approved a new testing system called Neuropsychiatric EEG-Based Assessment Aid (NEBA) System that measures electrical impulses that neurons give off within the brain to look for evidence of attention deficit hyperactivity disorder (ADHD) within a patient’s neural-net.
In less than a half an hour, the NEBA can calculate the ratio of specific brain wave frequencies such as theta na beta waves.
The target age group for NEBA is between 6 and 17.
Join us on our
Share this page with your friends
on your favorite social network: